Glucotrack reported steady progress in Q3 2025, focusing on strengthening its balance sheet and advancing its clinical development pipeline. The company secured flexible funding and expanded its clinical advisory team, positioning itself to fund operations through key milestones, including the anticipated FDA submission for its CBGM technology in Spring 2026.
Strengthened balance sheet with flexible funding, expected to fund operations through March 2026.
positiveExpanded clinical advisory team with the appointment of pain management and medical technology expert, Usman Latif, MD, MBA.
positiveImproved capital structure through repurchase of Series A Warrants, eliminating warrant liability and dilution overhang.
positivePresented poster at ADCES Annual Conference showing 73% of surveyed endocrinologists willing to prescribe CBGM product with 3-year sensor life.
positiveNet loss increased to $4.2 million ($4.64 per share) in Q3 2025, compared to a net loss of $5.1 million ($1,092 per share) in Q3 2024, though the reduction in net loss was attributed to prior year revaluation expenses.
attentionNet loss for the nine months ended September 30, 2025, increased to $15.8 million ($30.09 per share) from $12.5 million ($2,868 per share) in the prior year period, primarily due to increased G&A expenses and non-cash fair value change in derivative liabilities.
negativeResearch and development expenses increased to $3.2 million in Q3 2025 from $2.1 million in Q3 2024, primarily due to product and manufacturing development costs for the CBGM product.
attentionMarketing and general and administrative expenses increased to $4.4 million for the nine months ended September 30, 2025, from $2.9 million in the prior year period.
negativeInitiated a feasibility study in Australia that provided early learnings about health condition complexity impacting study eligibility, requiring protocol amendments and product improvements.
attentionMargin metrics will be available once backend extracts data from insights_json
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Continued steady progress towards corporate and clinical objectives.
Strengthened balance sheet by securing flexible funding to support key milestones.
Expanded clinical advisory team with addition of Dr. Latif.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.